AVEN抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Raji cells, Hela cells, Primary antibody: P10710(AVEN Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 2 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P10710(AVEN Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P10710(AVEN Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

AVEN antibody is a research tool targeting the AVEN protein, a regulator of apoptosis initially identified for its role in inhibiting programmed cell death. AVEN (Apoptosis and VSV-Expressing Protein) interacts with apoptotic protease-activating factor-1 (Apaf-1), a key component of the mitochondrial apoptosis pathway. By binding to Apaf-1. AVEN prevents the formation of the apoptosome, a multiprotein complex that activates caspase-9 and initiates the caspase cascade, ultimately suppressing apoptosis. This mechanism highlights AVEN's importance in cellular survival, particularly under stress conditions.

AVEN antibodies are primarily used in studies exploring apoptosis regulation, cancer biology, and neurodegenerative diseases. In cancer research, elevated AVEN expression has been linked to tumor progression and chemotherapy resistance, making it a potential therapeutic target. Antibodies against AVEN enable detection and quantification of the protein via techniques like Western blotting, immunohistochemistry, and flow cytometry, aiding in investigations of its expression patterns and functional roles.

Recent studies also suggest AVEN's involvement in DNA damage responses and autophagy, expanding its relevance beyond apoptosis. Researchers utilize AVEN antibodies to dissect these pathways in both in vitro and in vivo models. Commercial AVEN antibodies are typically raised in rabbits or mice, with specificity validated using knockout controls. As interest grows in targeting survival pathways for disease treatment, AVEN remains a focal point, and its antibodies continue to support advances in understanding cell death regulation and developing targeted therapies.